FIELD: medicine.
SUBSTANCE: invention relates to an anti-mesothelin antibody and a functional fragment thereof. The invention also discloses an antibody-drug conjugate targeting MSLNs. The conjugate contains a new anti-MSLN antibody or a functional fragment thereof containing engineered heavy and light chains, and a low molecular medicinal product. The present invention also discloses a method of synthesis of an antibody-drug conjugate (ADC) and the use of the conjugate for producing a medicinal product for treating a tumor.
EFFECT: proposed is anti-mesothelin antibody that can be used in treating tumors.
15 cl, 12 dwg, 4 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CLAUDIN 18.2 ANTIBODY AND ITS ANTIBODY-DRUG CONJUGATE | 2022 |
|
RU2814164C2 |
| ANTI-c-MET DRUG CONJUGATE AND USE THEREOF | 2021 |
|
RU2822497C1 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| FULLY HUMAN MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN | 2016 |
|
RU2748281C2 |
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS WITH ANTIBODIES AND RESULTING ADC | 2015 |
|
RU2773536C2 |
| ANTIBODIES WITH CYSTEINE SUBSTITUTIONS OBTAINED BY GENETIC ENGINEERING AND THEIR CONJUGATES | 2011 |
|
RU2755066C2 |
| ANTIBODY-DRUG CONJUGATES CONTAINING HERBOXYDIENE-BASED SPLICING MODULATOR, AND METHODS OF USE THEREOF | 2019 |
|
RU2820607C2 |
| SCREENING OF ATTACHMENT SITES WITH FIXED POINT IN CYSTEINE-MODIFIED ANTIBODY-TOXIN (TDC) CONJUGATE | 2018 |
|
RU2816510C2 |
| Cys80-CONJUGATED IMMUNOGLOBULINS | 2016 |
|
RU2756101C2 |
